Cell News and Research

RSS

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Progenika to provide blood group genotyping reference laboratory services to ARUP

Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

ImmunoGen to host a conference call to discuss its financial results

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company’s financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen’s 2010 fiscal year.

22 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) supports the permissive use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and young men ages 9 to 26, which means that GARDASIL may be given to males ages 9 to 26 to reduce the likelihood of acquiring genital warts at the discretion of the patient's health care provider.

22 Oct 2009

Scientists explore new molecular insights for treating anxiety disorders

There are increasingly precise molecular insights into ways that stress exposure leads to fear and through which fear extinction resolves these fear states. Extinction is generally regarded as new inhibitory learning, but where the inhibition originates from remains to be determined.

22 Oct 2009

Industries oppose proposed assisted living regulations

With Pennsylvania just weeks away from the publication of final assisted living regulations, recently-released survey results about the size of living units in existing facilities show the wisdom of the proposed rules -- and the absurdity of the industry's opposition.

22 Oct 2009

HBO treatments may improve neurological outcome after traumatic brain injury

Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced that researchers in its Slavica BioChem division have reported new positive results of experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored.

22 Oct 2009

Researchers develop a non-invasive test to help assess embryo viability for IVF

Embryos that are most likely to result in a pregnancy are crucial to the success of in vitro fertilization (IVF) but are difficult to identify. Researchers at Yale School of Medicine, led by Emre Seli, M.D., are developing a fast, non-invasive test to help assess embryo viability for IVF.

22 Oct 2009

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® (armodafinil) Tablets [C-IV].

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

22 Oct 2009

Alzheimer's Association Comfort Zone launched

Launched today, the Alzheimer's Association Comfort Zone(TM), powered by Omnilink, is the first comprehensive location management system designed specifically for Alzheimer's, giving people with the disease more freedom and independence in their community while providing their family some peace of mind.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that it has been selected to participate in a $3.7 million National Institutes of Health (NIH) Grand Opportunities (GO) grant awarded to The Johns Hopkins University.

22 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies’ collaboration formed in October 2007.

22 Oct 2009

HIV stigma: a barrier for proper care

The feeling of stigmatization that people living with HIV often experience doesn't only exact a psychological toll -new UCLA research suggests it can also lead to quantifiably negative health outcomes.

22 Oct 2009

Cell News and Research

Rosetta Genomics, GTG sign exclusive distribution agreement

Progenika to provide blood group genotyping reference laboratory services to ARUP

Celgene announces fiscal 2009 third-quarter results

ImmunoGen to host a conference call to discuss its financial results

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Advisory Committee on Immunization Practices supports the permissive use of GARDASIL

Scientists explore new molecular insights for treating anxiety disorders

Industries oppose proposed assisted living regulations

HBO treatments may improve neurological outcome after traumatic brain injury

Researchers develop a non-invasive test to help assess embryo viability for IVF

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Alzheimer's Association Comfort Zone launched

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

iPierian to participate in $3.7 million NIH grant awarded to The Johns Hopkins University

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

GE and Eli Lilly develop tissue-based biomarker technology for cancer therapy

HIV stigma: a barrier for proper care

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo